|
2024 Conference Publication Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)Hamid, A.A., Thomas, H., Martin, A., Soon, Y.Y., Horvath, L.G., Zielinski, R., Thomson, A., Tan, H., Sandhu, S.K., Reaume, M.N., Pook, D.W., Parnis, F., McDermott, R.S., Lawrence, N., Frydenberg, M., Chi, K.N., Stockler, M.R., Davis, I.D. and Sweeney, C. (2024). Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1699 |
|
2024 Conference Publication Dynamic change in tumour PSMA expression between baseline and day 15 after commencing enzalutamide in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901)Emmett, L., Swiha, M., Papa, N., Subramaniam, S., Crumbaker, M., Joshua, A., Nguyen, A., Weickhardt, A., Lee, S., Ng, S., Francis, R. J., Goh, J. C., Pattison, D. A., Sandhu, S., Pathmanandavel, S., Kumar, A. S. Ravi, Hofman, M. S., Gedye, C., Rutherford, N., Thomas, H., Martin, A. J., Stockler, M. S. and Davis, I. D. (2024). Dynamic change in tumour PSMA expression between baseline and day 15 after commencing enzalutamide in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): Findings from the randomised, phase 2, ENZA-p trial (ANZUP 1901). Annual Congress of the European Association of Nuclear Medicine, Hamburg, Germany, 19 - 23 October 2024. Heidelberg, Germany: Springer. |
|
2024 Conference Publication Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)Horvath, L.G., Lin, H-M., Davis, I.D., Martin, A., Scheinberg, T., Meikle, P., Joshua, A., Mcjannett, M., Subhash, V., Yip, S., North, S., McDermott, R.S., Chi, K.N., Stockler, M.R. and Sweeney, C. (2024). Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304). ESMO Congress 2024, Barcelona, Spain, 13-17 September 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.08.1688 |
|
2024 Journal Article Challenges of estimating treatment effects after a positive interim analysisSoon, Yu Yang, Marschner, Ian C., Schou, Manjula, Sweeney, Christopher J., Davis, Ian D., Stockler, Martin R. and Martin, Andrew J. (2024). Challenges of estimating treatment effects after a positive interim analysis. European Journal of Cancer, 209 114230, 114230. doi: 10.1016/j.ejca.2024.114230 |
|
2024 Conference Publication Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Kwan, Edmond Michael, Hofman, Michael S., Ng, Sarah W. S., Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Donnellan, Grainne, Annala, Matti, Tolmeijer, Sofie H., Azad, Arun, Davis, Ian D. and Wyatt, Alexander William (2024). Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). Special Clinical Science Symposia, Chicago, IL, United States, 29 May - 4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.5055 |
|
2024 Conference Publication Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [<sup>177</sup>Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Kwan, Edmond Michael, Hofman, Michael S., Ng, Sarah W. S., Emmett, Louise, Sandhu, Shahneen, Buteau, James Patrick, Iravani, Amir, Joshua, Anthony M., Francis, Roslyn J., Subhash, Vinod, Lee, Sze Ting, Scott, Andrew Mark, Martin, Andrew James, Stockler, Martin R., Donnellan, Gráinne, Annala, Matti, Tolmeijer, Sofie H., Azad, Arun, Davis, Ian D., Wyatt, Alexander William and TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May-4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.5055 |
|
2024 Journal Article Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3)Nahm, Sharon H., Stockler, Martin R., Martin, Andrew J., Grimison, Peter, Fox, Peter, Zielinski, Rob, Hawson, Geoffrey AT., Tattersall, Martin HN. and Kiely, Belinda E. (2024). Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3). Supportive Care in Cancer, 32 (6) 386. doi: 10.1007/s00520-024-08597-x |
|
2024 Journal Article [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trialEmmett, Louise, Subramaniam, Shalini, Crumbaker, Megan, Nguyen, Andrew, Joshua, Anthony M., Weickhardt, Andrew, Lee, Sze-Ting, Ng, Siobhan, Francis, Roslyn J., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Gedye, Craig, Rutherford, Natalie K., Sandhu, Shahneen, Kumar, Aravind Ravi, Pook, David, Ramdave, Shakher, Nadebaum, David P., Voskoboynik, Mark, Redfern, Andrew D., Macdonald, William, Krieger, Laurence, Schembri, Geoff, Chua, Wei, Lin, Peter, Horvath, Lisa, Bastick, Patricia ... Davis, Ian D. (2024). [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. The Lancet Oncology, 25 (5), 563-571. doi: 10.1016/s1470-2045(24)00135-9 |
|
2024 Journal Article Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trialGafita, Andrei, Martin, Andrew J., Emmett, Louise, Eiber, Matthias, Iravani, Amir, Fendler, Wolfgang P., Buteau, James, Sandhu, Shahneen, Azad, Arun A, Herrmann, Ken, Stockler, Martin R., Davis, Ian D. and Hofman, Michael S. (2024). Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trial. European Urology Oncology, 8 (1), 21-28. doi: 10.1016/j.euo.2024.03.009 |
|
2024 Journal Article Characterization of Wearable Respiratory Sensors for Breathing Parameter MeasurementsSabz, Mozhgan, MacLean, Joanna, Martin, Andrew R. and Rouhani, Hossein (2024). Characterization of Wearable Respiratory Sensors for Breathing Parameter Measurements. IEEE Sensors Journal, 24 (20), 32283-32290. doi: 10.1109/jsen.2024.3448539 |
|
2024 Journal Article Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation frameworkCho, Doah, Lord, Sarah J., Ward, Robyn, IJzerman, Maarten, Mitchell, Andrew, Thomas, David M., Cheyne, Saskia, Martin, Andrew, Morton, Rachael L., Simes, John and Lee, Chee Khoon (2024). Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework. Therapeutic Advances in Medical Oncology, 16, 1-20. doi: 10.1177/17588359241273062 |
|
2024 Journal Article Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialHofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Buteau, James P., Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Weickhardt, Andrew, Scott, Andrew M., Lee, Sze-Ting, Kwan, Edmond M., Azad, Arun A., Ramdave, Shakher, Redfern, Andrew D., Macdonald, William, Guminski, Alex, Hsiao, Edward, Chua, Wei, Lin, Peter, Zhang, Alison Yan, Stockler, Martin R., Williams, Scott G. ... Yip, Sonia (2024). Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. The Lancet Oncology, 25 (1), 99-107. doi: 10.1016/s1470-2045(23)00529-6 |
|
2024 Journal Article Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative studyGore, Claire, Lisy, Karolina, O’Callaghan, Clare, Wood, Colin, Emery, Jon, Martin, Andrew, De Abreu Lourenco, Richard, Schofield, Penelope and Jefford, Michael (2024). Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: a qualitative study. Psycho-Oncology, 33 (1) e6265. doi: 10.1002/pon.6265 |
|
2023 Journal Article Accuracy of oncologists' estimates of expected survival time in advanced cancerNahm, Sharon H., Martin, Andrew J., Clayton, Josephine M., Grimison, Peter, Moth, Erin B., Pavlakis, Nick, Sjoquist, Katrin, Smith-Uffen, Megan E. S., Tognela, Annette, Vasista, Anuradha, Stockler, Martin R. and Kiely, Belinda E. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7 (6) pkad094. doi: 10.1093/jncics/pkad094 |
|
2023 Journal Article SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancerJefford, Michael, Emery, Jon D., James Martin, Andrew, De Abreu Lourenco, Richard, Lisy, Karolina, Grunfeld, Eva, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer. eClinicalMedicine, 66 102346, 1-11. doi: 10.1016/j.eclinm.2023.102346 |
|
2023 Conference Publication Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)Horvath, L. G., Davis, I. D., Martin, A., Zielinski, R., Thomson, A., Tan, T. H., Sandhu, S. K., Reaume, M. N., Pook, D., Parnis, F., North, S., Marx, G. M., McCaffrey, J. A., McDermott, R. S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K. N. N., Stockler, M. R. and Sweeney, C. (2023). Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2742 |
|
2023 Conference Publication Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., Tan, H., Kirkwood, I. D., Sandhu, S. K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M. R. and Davis, I. D. (2023). Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.10.086 |
|
2023 Conference Publication Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)Gedye, C., Harris, C. A., Stockler, M. R., Morris, M., Ferguson, T., Goh, J. C. H., Martin, A., Underhill, C. R., Pook, D., Krieger, L. E. M., Kichenadasse, G., Joshi, A. J., Subramaniam, S., Zebic, D. S., Zhang, A., Joshua, A. M., Toner, G. C., Vasey, P. A., Prithviraj, P. and Davis, I. D. (2023). Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.1116 |
|
2023 Journal Article Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancerSjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R. and Simes, R. John (2023). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. Journal of Cancer Research and Clinical Oncology, 149 (8), 4959-4965. doi: 10.1007/s00432-022-04404-4 |
|
2023 Journal Article Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. ReplyAllen, Nicholas C., Martin, Andrew J. and Damian, Diona L. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. Reply. The New England journal of medicine, 388 (26), 2494-2495. doi: 10.1056/NEJMc2303841 |
